TALLAHASSEE, Fla., May 21, 2012 /PRNewswire/ -- The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today discredited recommendations by the U.S. Preventive Services Task Force (USPSTF) to stop prostate cancer testing.
USPSTF's final recommendation, released today, instructs physicians to discourage asymptomatic men from having the PSA test. This comes despite overwhelming opposition from urologists, prostate cancer patients, and patient advocacy groups, all who have confirmed the importance of these life-saving measures.
"We are appalled at the USPSTF's recommendation that healthy men should no longer receive prostate-specific antigen (PSA) blood tests as part of routine cancer screening," said Dr. Deepak A. Kapoor, President of LUGPA and Chairman and CEO of Integrated Medical Professionals, PLLC. Kapoor added, "Failing to detect cancer early will create a public health catastrophe in 5-10 years."
The largest study on screening, the European Randomized Study for the Screening of Prostate Cancer (ERSPC) published its updated findings in the March issue of the New England Journal of Medicine. This demonstrated a 21 percent survival advantage to PSA screening for all patients, and furthermore, for those with the longest follow-up (over 10 years) this increased to 38 percent. This is consistent with experience in the United States, where death rates from prostate cancer have declined by nearly 40 percent over the last two decades, although the incidence of the disease has been relatively stable.
Dr. Kapoor states, "USPSTF clearly 'cherry-picked' data to support what can only be viewed as a pre-conceived bias against screening. The task force did not include any physician who treats prostate cancer, and ignored credible studies and epidemiological data demonstrating a significant survival advantage to early detection…we
|SOURCE Large Urology Group Practice Association|
Copyright©2010 PR Newswire.
All rights reserved